Phathom Pharmaceuticals, Inc. (PHAT) 10-Year Financial Performance & Capital Metrics

PHAT • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutPhathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Show more

Revenue $55M +8001.5%
EBITDA -$277M -65.9%
Net Income -$334M -65.8%
EPS (Diluted) -5.29 -34.6%
Gross Margin 85.57% +13.3%
EBITDA Margin -500.75% +98.0%
Operating Margin -502.18% +98.0%
Net Margin -605.09% +98.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -3.85 +3.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 23.2% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM460.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.12%

EPS CAGR

10Y-

5Y-

3Y-

TTM32.86%

ROCE

10Y Avg-76.83%

5Y Avg-75.34%

3Y Avg-86.62%

Latest-83.12%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	682K	55.25M
Revenue Growth %	-	-	-	-	-	-	80.01%
Cost of Goods Sold+	0	8K	300K	521K	620K	167K	7.97M
COGS % of Revenue	-	-	-	-	-	0.24%	0.14%
Gross Profit+	0	-8K	-300K	-521K	-620K	515K	47.28M
Gross Margin %	-	-	-	-	-	0.76%	0.86%
Gross Profit Growth %	-	-	-36.5%	-0.74%	-0.19%	1.83%	90.8%
Operating Expenses+	1.23M	106.22M	125.36M	134.56M	171.82M	167.83M	324.75M
OpEx % of Revenue	-	-	-	-	-	246.08%	5.88%
Selling, General & Admin	1.21M	6.94M	27.22M	62.22M	100.38M	117.93M	290.66M
SG&A % of Revenue	-	-	-	-	-	172.91%	5.26%
Research & Development	20K	99.27M	98.15M	72.34M	71.44M	49.9M	34.08M
R&D % of Revenue	-	-	-	-	-	73.17%	0.62%
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-1.23M	-106.22M	-125.67M	-135.08M	-172.44M	-167.31M	-277.47M
Operating Margin %	-	-	-	-	-	-245.33%	-5.02%
Operating Income Growth %	-	-85.71%	-0.18%	-0.07%	-0.28%	0.03%	-0.66%
EBITDA+	0	-106.21M	-125.36M	-134.56M	-171.82M	-166.74M	-276.67M
EBITDA Margin %	-	-	-	-	-	-244.48%	-5.01%
EBITDA Growth %	-	-	-0.18%	-0.07%	-0.28%	0.03%	-0.66%
D&A (Non-Cash Add-back)	1.23M	8K	300K	521K	620K	575K	795K
EBIT	-1.27M	-250.95M	-124.49M	-137.09M	-170.42M	-159.62M	-262.32M
Net Interest Income+	0	-3.09M	-3.49M	-6.75M	-25.17M	-34.09M	-56.85M
Interest Income	0	1.09M	1.09M	41K	2.13M	7.88M	15.16M
Interest Expense	13K	4.18M	4.58M	6.79M	27.3M	41.97M	72.01M
Other Income/Expense	-63K	-148.92M	-3.4M	-8.8M	-25.28M	-34.28M	-56.86M
Pretax Income+	-1.29M	-255.13M	-129.07M	-143.88M	-197.72M	-201.59M	-334.33M
Pretax Margin %	-	-	-	-	-	-295.59%	-6.05%
Income Tax+	13K	0	0	0	0	0	0
Effective Tax Rate %	1%	0.82%	1%	1%	1%	1%	1%
Net Income+	-1.29M	-209.74M	-129.07M	-143.88M	-197.72M	-201.59M	-334.33M
Net Margin %	-	-	-	-	-	-295.59%	-6.05%
Net Income Growth %	-	-161.84%	0.38%	-0.11%	-0.37%	-0.02%	-0.66%
Net Income (Continuing)	-1.29M	-255.13M	-129.07M	-143.88M	-197.72M	-201.59M	-334.33M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.15	-8.48	-4.01	-4.00	-5.70	-3.93	-5.29
EPS Growth %	-	-55.53%	0.53%	0%	-0.42%	0.31%	-0.35%
EPS (Basic)	-0.15	-8.48	-4.01	-4.00	-5.70	-3.93	-5.29
Diluted Shares Outstanding	8.58M	24.73M	33.23M	37M	39.12M	51.29M	63.18M
Basic Shares Outstanding	8.58M	24.73M	33.23M	37M	39.12M	51.29M	63.18M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	902K	255.6M	291.37M	186.53M	160.51M	397.43M	360.13M
Cash & Short-Term Investments	879K	243.76M	287.5M	183.26M	155.38M	381.39M	297.26M
Cash Only	879K	243.76M	287.5M	183.26M	155.38M	381.39M	297.26M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	0	0	82K	0	0	1.64M	38.8M
Days Sales Outstanding	-	-	-	-	-	876.11	256.3
Inventory	0	0	-82K	0	0	1.21M	3.21M
Days Inventory Outstanding	-	-	-	-	-	2.64K	146.86
Other Current Assets	0	0	3.87M	3.27M	5.13M	13.19M	20.87M
Total Non-Current Assets+	0	1.58M	3.74M	2.9M	4.3M	16.41M	18.18M
Property, Plant & Equipment	0	1.4M	3.36M	2.56M	3.49M	3.62M	2.09M
Fixed Asset Turnover	-	-	-	-	-	0.19x	26.45x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	505K	0	2.86M
Other Non-Current Assets	0	181K	384K	341K	299K	12.79M	13.23M
Total Assets+	902K	257.18M	295.11M	189.43M	164.81M	413.84M	378.32M
Asset Turnover	-	-	-	-	-	0.00x	0.15x
Asset Growth %	-	284.12%	0.15%	-0.36%	-0.13%	1.51%	-0.09%
Total Current Liabilities+	2.19M	3.75M	55.52M	18.92M	26.24M	38.78M	85.73M
Accounts Payable	55K	699K	16.78M	5.15M	10M	12.6M	10.51M
Days Payables Outstanding	-	31.89K	20.42K	3.61K	5.89K	27.54K	481.01
Short-Term Debt	1.95M	0	7.35M	0	0	0	19.78M
Deferred Revenue (Current)	-1000K	0	0	0	0	0	0
Other Current Liabilities	0	413K	0	0	0	20.43M	54.94M
Current Ratio	0.41x	68.20x	5.25x	9.86x	6.12x	10.25x	4.20x
Quick Ratio	0.41x	68.20x	5.25x	9.86x	6.12x	10.22x	4.16x
Cash Conversion Cycle	-	-	-	-	-	-24.02K	-77.85
Total Non-Current Liabilities+	0	25.48M	45.32M	98.35M	213.39M	447.82M	546.17M
Long-Term Debt	0	22.78M	39.63M	89.67M	95.26M	137.84M	534.67M
Capital Lease Obligations	0	635K	1.56M	1.18M	1.1M	462K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	2.06M	4.13M	7.5M	117.03M	309.52M	11.5M
Total Liabilities	2.19M	29.22M	100.84M	117.28M	239.62M	486.6M	631.9M
Total Debt+	1.95M	23.57M	49.02M	91.34M	97.07M	139.03M	554.95M
Net Debt	1.07M	-220.19M	-238.48M	-91.92M	-58.31M	-242.36M	257.68M
Debt / Equity	-	0.10x	0.25x	1.27x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-94.23x	-25.43x	-27.43x	-19.90x	-6.32x	-3.99x	-3.85x
Total Equity+	-1.29M	227.96M	194.27M	72.16M	-74.81M	-72.76M	-253.58M
Equity Growth %	-	178.26%	-0.15%	-0.63%	-2.04%	0.03%	-2.49%
Book Value per Share	-0.15	9.22	5.85	1.95	-1.91	-1.42	-4.01
Total Shareholders' Equity	-1.29M	227.96M	194.27M	72.16M	-74.81M	-72.76M	-253.58M
Common Stock	0	2K	3K	3K	3K	5K	6K
Retained Earnings	-1.29M	-256.42M	-385.49M	-529.37M	-727.09M	-928.68M	-1.26B
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.02M	-36.51M	-69.69M	-148.46M	-146.53M	-137.58M	-266.77M
Operating CF Margin %	-	-	-	-	-	-201.73%	-4.83%
Operating CF Growth %	-	-34.69%	-0.91%	-1.13%	0.01%	0.06%	-0.94%
Net Income	-1.29M	-255.13M	-129.07M	-143.88M	-197.72M	-201.59M	-334.33M
Depreciation & Amortization	0	8K	323K	521K	620K	575K	795K
Stock-Based Compensation	0	406K	5.84M	16.81M	0	45.02M	24.05M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	50K	227.73M	1.5M	5.41M	45.13M	32.06M	58.01M
Working Capital Changes	215K	-9.52M	51.72M	-27.32M	5.44M	-13.64M	-15.3M
Change in Receivables	0	0	0	0	0	-1.64M	-37.16M
Change in Inventory	0	0	0	0	0	-9.44M	-6.14M
Change in Payables	225K	2.27M	24.01M	-9.79M	8.68M	6.41M	34.94M
Cash from Investing+	0	-25.25M	-1.04M	-328K	-1.04M	-1.63M	-135K
Capital Expenditures	0	-132K	-1.04M	-328K	-1.04M	-1.63M	-135K
CapEx % of Revenue	-	-	-	-	-	2.4%	0%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	-25.12M	0	0	0	0	0
Cash from Financing+	1.9M	304.65M	114.46M	44.71M	120.04M	367.58M	182.77M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	2K	0	629K	1.94M	0	172.8M	1.6M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-1.02M	-61.76M	-70.73M	-148.78M	-147.57M	-139.21M	-266.9M
FCF Margin %	-	-	-	-	-	-204.13%	-4.83%
FCF Growth %	-	-59.37%	-0.15%	-1.1%	0.01%	0.06%	-0.92%
FCF per Share	-0.12	-2.50	-2.13	-4.02	-3.77	-2.71	-4.22
FCF Conversion (FCF/Net Income)	0.79x	0.17x	0.54x	1.03x	0.74x	0.68x	0.80x
Interest Paid	0	1.01M	3.46M	4.07M	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-185.07%	-61.14%	-108.01%	-	-	-
Return on Invested Capital (ROIC)	-	-2110.79%	-	-	-	-	-
Gross Margin	-	-	-	-	-	75.51%	85.57%
Net Margin	-	-	-	-	-	-29558.94%	-605.09%
Debt / Equity	-	0.10x	0.25x	1.27x	-	-	-
Interest Coverage	-94.23x	-25.43x	-27.43x	-19.90x	-6.32x	-3.99x	-3.85x
FCF Conversion	0.79x	0.17x	0.54x	1.03x	0.74x	0.68x	0.80x
Revenue Growth	-	-	-	-	-	-	8001.47%

Frequently Asked Questions

Growth & Financials

Phathom Pharmaceuticals, Inc. (PHAT) reported $147.2M in revenue for fiscal year 2024.

Phathom Pharmaceuticals, Inc. (PHAT) grew revenue by 8001.5% over the past year. This is strong growth.

Phathom Pharmaceuticals, Inc. (PHAT) reported a net loss of $274.6M for fiscal year 2024.

Dividend & Returns

Phathom Pharmaceuticals, Inc. (PHAT) had negative free cash flow of $225.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Phathom Pharmaceuticals, Inc. (PHAT) 10-Year Financial Performance & Capital Metrics

PHAT • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $55M +8001.5%
EBITDA -$277M -65.9%
Net Income -$334M -65.8%
EPS (Diluted) -5.29 -34.6%
Gross Margin 85.57% +13.3%
EBITDA Margin -500.75% +98.0%
Operating Margin -502.18% +98.0%
Net Margin -605.09% +98.0%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -3.85 +3.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 23.2% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM460.3%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM19.12%

EPS CAGR

10Y-

5Y-

3Y-

TTM32.86%

ROCE

10Y Avg-76.83%

5Y Avg-75.34%

3Y Avg-86.62%

Latest-83.12%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	682K	55.25M
Revenue Growth %	-	-	-	-	-	-	80.01%
Cost of Goods Sold+	0	8K	300K	521K	620K	167K	7.97M
COGS % of Revenue	-	-	-	-	-	0.24%	0.14%
Gross Profit+	0	-8K	-300K	-521K	-620K	515K	47.28M
Gross Margin %	-	-	-	-	-	0.76%	0.86%
Gross Profit Growth %	-	-	-36.5%	-0.74%	-0.19%	1.83%	90.8%
Operating Expenses+	1.23M	106.22M	125.36M	134.56M	171.82M	167.83M	324.75M
OpEx % of Revenue	-	-	-	-	-	246.08%	5.88%
Selling, General & Admin	1.21M	6.94M	27.22M	62.22M	100.38M	117.93M	290.66M
SG&A % of Revenue	-	-	-	-	-	172.91%	5.26%
Research & Development	20K	99.27M	98.15M	72.34M	71.44M	49.9M	34.08M
R&D % of Revenue	-	-	-	-	-	73.17%	0.62%
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income+	-1.23M	-106.22M	-125.67M	-135.08M	-172.44M	-167.31M	-277.47M
Operating Margin %	-	-	-	-	-	-245.33%	-5.02%
Operating Income Growth %	-	-85.71%	-0.18%	-0.07%	-0.28%	0.03%	-0.66%
EBITDA+	0	-106.21M	-125.36M	-134.56M	-171.82M	-166.74M	-276.67M
EBITDA Margin %	-	-	-	-	-	-244.48%	-5.01%
EBITDA Growth %	-	-	-0.18%	-0.07%	-0.28%	0.03%	-0.66%
D&A (Non-Cash Add-back)	1.23M	8K	300K	521K	620K	575K	795K
EBIT	-1.27M	-250.95M	-124.49M	-137.09M	-170.42M	-159.62M	-262.32M
Net Interest Income+	0	-3.09M	-3.49M	-6.75M	-25.17M	-34.09M	-56.85M
Interest Income	0	1.09M	1.09M	41K	2.13M	7.88M	15.16M
Interest Expense	13K	4.18M	4.58M	6.79M	27.3M	41.97M	72.01M
Other Income/Expense	-63K	-148.92M	-3.4M	-8.8M	-25.28M	-34.28M	-56.86M
Pretax Income+	-1.29M	-255.13M	-129.07M	-143.88M	-197.72M	-201.59M	-334.33M
Pretax Margin %	-	-	-	-	-	-295.59%	-6.05%
Income Tax+	13K	0	0	0	0	0	0
Effective Tax Rate %	1%	0.82%	1%	1%	1%	1%	1%
Net Income+	-1.29M	-209.74M	-129.07M	-143.88M	-197.72M	-201.59M	-334.33M
Net Margin %	-	-	-	-	-	-295.59%	-6.05%
Net Income Growth %	-	-161.84%	0.38%	-0.11%	-0.37%	-0.02%	-0.66%
Net Income (Continuing)	-1.29M	-255.13M	-129.07M	-143.88M	-197.72M	-201.59M	-334.33M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.15	-8.48	-4.01	-4.00	-5.70	-3.93	-5.29
EPS Growth %	-	-55.53%	0.53%	0%	-0.42%	0.31%	-0.35%
EPS (Basic)	-0.15	-8.48	-4.01	-4.00	-5.70	-3.93	-5.29
Diluted Shares Outstanding	8.58M	24.73M	33.23M	37M	39.12M	51.29M	63.18M
Basic Shares Outstanding	8.58M	24.73M	33.23M	37M	39.12M	51.29M	63.18M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	902K	255.6M	291.37M	186.53M	160.51M	397.43M	360.13M
Cash & Short-Term Investments	879K	243.76M	287.5M	183.26M	155.38M	381.39M	297.26M
Cash Only	879K	243.76M	287.5M	183.26M	155.38M	381.39M	297.26M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	0	0	82K	0	0	1.64M	38.8M
Days Sales Outstanding	-	-	-	-	-	876.11	256.3
Inventory	0	0	-82K	0	0	1.21M	3.21M
Days Inventory Outstanding	-	-	-	-	-	2.64K	146.86
Other Current Assets	0	0	3.87M	3.27M	5.13M	13.19M	20.87M
Total Non-Current Assets+	0	1.58M	3.74M	2.9M	4.3M	16.41M	18.18M
Property, Plant & Equipment	0	1.4M	3.36M	2.56M	3.49M	3.62M	2.09M
Fixed Asset Turnover	-	-	-	-	-	0.19x	26.45x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	505K	0	2.86M
Other Non-Current Assets	0	181K	384K	341K	299K	12.79M	13.23M
Total Assets+	902K	257.18M	295.11M	189.43M	164.81M	413.84M	378.32M
Asset Turnover	-	-	-	-	-	0.00x	0.15x
Asset Growth %	-	284.12%	0.15%	-0.36%	-0.13%	1.51%	-0.09%
Total Current Liabilities+	2.19M	3.75M	55.52M	18.92M	26.24M	38.78M	85.73M
Accounts Payable	55K	699K	16.78M	5.15M	10M	12.6M	10.51M
Days Payables Outstanding	-	31.89K	20.42K	3.61K	5.89K	27.54K	481.01
Short-Term Debt	1.95M	0	7.35M	0	0	0	19.78M
Deferred Revenue (Current)	-1000K	0	0	0	0	0	0
Other Current Liabilities	0	413K	0	0	0	20.43M	54.94M
Current Ratio	0.41x	68.20x	5.25x	9.86x	6.12x	10.25x	4.20x
Quick Ratio	0.41x	68.20x	5.25x	9.86x	6.12x	10.22x	4.16x
Cash Conversion Cycle	-	-	-	-	-	-24.02K	-77.85
Total Non-Current Liabilities+	0	25.48M	45.32M	98.35M	213.39M	447.82M	546.17M
Long-Term Debt	0	22.78M	39.63M	89.67M	95.26M	137.84M	534.67M
Capital Lease Obligations	0	635K	1.56M	1.18M	1.1M	462K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	2.06M	4.13M	7.5M	117.03M	309.52M	11.5M
Total Liabilities	2.19M	29.22M	100.84M	117.28M	239.62M	486.6M	631.9M
Total Debt+	1.95M	23.57M	49.02M	91.34M	97.07M	139.03M	554.95M
Net Debt	1.07M	-220.19M	-238.48M	-91.92M	-58.31M	-242.36M	257.68M
Debt / Equity	-	0.10x	0.25x	1.27x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-94.23x	-25.43x	-27.43x	-19.90x	-6.32x	-3.99x	-3.85x
Total Equity+	-1.29M	227.96M	194.27M	72.16M	-74.81M	-72.76M	-253.58M
Equity Growth %	-	178.26%	-0.15%	-0.63%	-2.04%	0.03%	-2.49%
Book Value per Share	-0.15	9.22	5.85	1.95	-1.91	-1.42	-4.01
Total Shareholders' Equity	-1.29M	227.96M	194.27M	72.16M	-74.81M	-72.76M	-253.58M
Common Stock	0	2K	3K	3K	3K	5K	6K
Retained Earnings	-1.29M	-256.42M	-385.49M	-529.37M	-727.09M	-928.68M	-1.26B
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.02M	-36.51M	-69.69M	-148.46M	-146.53M	-137.58M	-266.77M
Operating CF Margin %	-	-	-	-	-	-201.73%	-4.83%
Operating CF Growth %	-	-34.69%	-0.91%	-1.13%	0.01%	0.06%	-0.94%
Net Income	-1.29M	-255.13M	-129.07M	-143.88M	-197.72M	-201.59M	-334.33M
Depreciation & Amortization	0	8K	323K	521K	620K	575K	795K
Stock-Based Compensation	0	406K	5.84M	16.81M	0	45.02M	24.05M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	50K	227.73M	1.5M	5.41M	45.13M	32.06M	58.01M
Working Capital Changes	215K	-9.52M	51.72M	-27.32M	5.44M	-13.64M	-15.3M
Change in Receivables	0	0	0	0	0	-1.64M	-37.16M
Change in Inventory	0	0	0	0	0	-9.44M	-6.14M
Change in Payables	225K	2.27M	24.01M	-9.79M	8.68M	6.41M	34.94M
Cash from Investing+	0	-25.25M	-1.04M	-328K	-1.04M	-1.63M	-135K
Capital Expenditures	0	-132K	-1.04M	-328K	-1.04M	-1.63M	-135K
CapEx % of Revenue	-	-	-	-	-	2.4%	0%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	-25.12M	0	0	0	0	0
Cash from Financing+	1.9M	304.65M	114.46M	44.71M	120.04M	367.58M	182.77M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	2K	0	629K	1.94M	0	172.8M	1.6M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-1.02M	-61.76M	-70.73M	-148.78M	-147.57M	-139.21M	-266.9M
FCF Margin %	-	-	-	-	-	-204.13%	-4.83%
FCF Growth %	-	-59.37%	-0.15%	-1.1%	0.01%	0.06%	-0.92%
FCF per Share	-0.12	-2.50	-2.13	-4.02	-3.77	-2.71	-4.22
FCF Conversion (FCF/Net Income)	0.79x	0.17x	0.54x	1.03x	0.74x	0.68x	0.80x
Interest Paid	0	1.01M	3.46M	4.07M	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-185.07%	-61.14%	-108.01%	-	-	-
Return on Invested Capital (ROIC)	-	-2110.79%	-	-	-	-	-
Gross Margin	-	-	-	-	-	75.51%	85.57%
Net Margin	-	-	-	-	-	-29558.94%	-605.09%
Debt / Equity	-	0.10x	0.25x	1.27x	-	-	-
Interest Coverage	-94.23x	-25.43x	-27.43x	-19.90x	-6.32x	-3.99x	-3.85x
FCF Conversion	0.79x	0.17x	0.54x	1.03x	0.74x	0.68x	0.80x
Revenue Growth	-	-	-	-	-	-	8001.47%

Frequently Asked Questions

Growth & Financials

Phathom Pharmaceuticals, Inc. (PHAT) reported $147.2M in revenue for fiscal year 2024.

Phathom Pharmaceuticals, Inc. (PHAT) grew revenue by 8001.5% over the past year. This is strong growth.

Phathom Pharmaceuticals, Inc. (PHAT) reported a net loss of $274.6M for fiscal year 2024.

Dividend & Returns

Phathom Pharmaceuticals, Inc. (PHAT) had negative free cash flow of $225.3M in fiscal year 2024, likely due to heavy capital investments.